Denali therapeutics announces presentations on dnl310 (etv:ids) development program in mps ii (hunter syndrome) at the upcoming worldsymposium™

South san francisco, calif., feb. 01, 2022 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced upcoming presentations from the dnl310 (etv:ids) clinical development program to be given at the 18th annual worldsymposium™, which will be held february 7-11, 2022, in san diego, california, and virtually. dnl310 is an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (cns) and peripheral manifestations of mps ii (hunter syndrome).
DNLI Ratings Summary
DNLI Quant Ranking